GT Biopharma Past Earnings Performance

Past criteria checks 0/6

GT Biopharma has been growing earnings at an average annual rate of 55.4%, while the Biotechs industry saw earnings growing at 17.7% annually.

Key information

55.4%

Earnings growth rate

83.8%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth raten/a
Return on equity-101.6%
Net Marginn/a
Last Earnings Update31 Dec 2023

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How GT Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:OXIA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 230-876
30 Sep 230-1088
30 Jun 230-15119
31 Mar 230-16118
31 Dec 220-21129
30 Sep 220-332112
30 Jun 220-322211
31 Mar 220-342410
31 Dec 210-584810
30 Sep 210-46384
30 Jun 210-44352
31 Mar 210-56332
31 Dec 200-2860
30 Sep 200-2350
30 Jun 200-5071
31 Mar 200-3671
31 Dec 190-39102
30 Sep 190-41113
30 Jun 190-247123
31 Mar 190-254126
31 Dec 180-259129
30 Sep 180-261168
30 Jun 180-1561387
31 Mar 180-1491374
31 Dec 170-1441351
30 Sep 170-1411291
30 Jun 170-1451
31 Mar 170-1061
31 Dec 1601081
30 Sep 160-14101
30 Jun 160-12101
31 Mar 16014101
31 Dec 150-2181
30 Sep 150-1470
30 Jun 150-1750
31 Mar 150-4440
31 Dec 140-2320
30 Sep 140-510
30 Jun 140-110
31 Mar 140-110
31 Dec 130-110
30 Sep 131-120
30 Jun 130-230

Quality Earnings: OXIA is currently unprofitable.

Growing Profit Margin: OXIA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: OXIA is unprofitable, but has reduced losses over the past 5 years at a rate of 55.4% per year.

Accelerating Growth: Unable to compare OXIA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OXIA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).


Return on Equity

High ROE: OXIA has a negative Return on Equity (-101.62%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies